A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) is a phase 2 interventional study registered as NCT07082686 by Beijing InnoCare Pharma Tech Co., Ltd., with 75 participants planned, started 2025-08-21 and due to reach its primary completion in 2027-12. Interventions recorded: ICP-248. Conditions listed: Relapsed or Refractory Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.